Last Update Time:
04-Mar-2025 16:00:00
ISIN:
INE203A01020
Sector:
Healthcare
Symbol:
ASTRAZEN
AstraZeneca Pharma India Limited
₹7,339.00
₹480.80
(7.01%)
▲
Prev. Close
₹6,858.20
Open
₹6,868.25
Close
₹7,306.25
Range
₹6,972.05 - ₹7,705.95
High
₹7,397.00
Low
₹6,730.05
Ind. Close
₹0.00
VWAP
₹7,238.75
The current stock price of AstraZeneca Pharma India Limited is ₹7,339.00, with a target price range between ₹6,972.05 and ₹7,705.95. The stock has experienced a price change of ₹480.80 (7.01%), reflecting recent market volatility.
Today's opening price was ₹6,868.25, while the previous close stood at ₹6,858.20.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
AstraZeneca Pharma India Limited Price Chart
AstraZeneca Pharma India Limited Pre Open Market Overview: 04-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 6868.25
- Previous Close Price: 6858.2
- Change: 10.05%
- Total Traded Volume: 79
- Total Buy Quantity: 817
- Total Sell Quantity: 151
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 6,755.35 | 3.00 | 0.00 |
| 6,767.00 | 10.00 | 0.00 |
| 6,800.00 | 2.00 | 0.00 |
| 6,860.00 | 3.00 | 0.00 |
| 6,868.25 | 0.00 | 0.00 |
| 6,870.00 | 59.00 | 0.00 |
| 6,890.00 | 0.00 | 15.00 |
| 6,913.00 | 0.00 | 2.00 |
| 6,942.65 | 0.00 | 4.00 |
| 6,942.90 | 0.00 | 2.00 |
| 6,943.05 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 817
Total Sell Quantity: 151
Shareholding Patterns of AstraZeneca Pharma India Limited
Key Trade Statistics of AstraZeneca Pharma India Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.02 |
| Traded Value (₹ Cr.) | 74.07 |
| Total Market Cap (₹ Cr.) | 18,347.50 |
| Free Float Market Cap (₹ Cr.) | 4,510.33 |
| Impact cost | 0.09 |
| Quantity Traded | 102,327.00 |
| Deliverable Quantity | 26,891.00 |
| % of Quantity to Traded | 26.28 |
| Security VaR | 16.96 |
| Index VaR | N/A |
| VaR Margin | 16.96 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 20.46 |
| Face Value | 2 |
Key Price Statistics of AstraZeneca Pharma India Limited
The 52-week high for AstraZeneca Pharma India Limited was ₹8,139.00, recorded on 07-Oct-2024. On the other hand, the 52-week low stands at ₹4,785.00, with the lowest value recorded on 14-Mar-2024.
The upper band for trading is ₹8,229.80, and the lower band is ₹5,486.60. The price band is 20%.
The stock's daily volatility stands at 2.61, while the annualized volatility is 49.86. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (07-Oct-2024) | 8,139.00 |
| 52 Week Low (14-Mar-2024) | 4,785.00 |
| Upper Band | 8,229.80 |
| Lower Band | 5,486.60 |
| Price Band (%) | 20 |
| Daily Volatility | 2.61 |
| Annualised Volatility | 49.86 |
| Tick Size | 0.05 |
Key Securities Statistics of AstraZeneca Pharma India Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 04-May-2001 |
| Adjusted P/E | 78.22 |
| Symbol P/E | 176.81 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of AstraZeneca Pharma India Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of AstraZeneca Pharma India Limited
| Subject | Date |
|---|---|
| Updates | 28-Feb-2025 |
| Copy of Newspaper Publication | 25-Feb-2025 |
| Notice Of Shareholders Meetings-XBRL | 25-Feb-2025 |
| Updates | 25-Feb-2025 |
| Shareholders meeting | 24-Feb-2025 |
| Integrated Filing- Financial | 17-Feb-2025 |
| Copy of Newspaper Publication | 14-Feb-2025 |
| Financial Result Updates | 11-Feb-2025 |
Corporate Actions of AstraZeneca Pharma India Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Dividend - Rs 24 Per Share | 05-Jul-2024 |
| 2 | Dividend - Rs 16 Per Share | 14-Jul-2023 |
| 2 | Dividend - Rs 8 Per Share | 07-Jul-2022 |
| 2 | Interim Dividend - Rs 2 Per Share | 18-Aug-2021 |
| 2 | Interim Dividend - Rs 2 Per Share | 20-Aug-2020 |
| 2 | Interim Dividend - Re 1 Per Share | 20-Aug-2019 |
| 2 | Annual General Meeting | 30-Aug-2018 |
| 2 | Annual General Meeting | 04-Sep-2017 |
| 2 | Annual General Meeting | 02-Aug-2016 |
| 2 | Annual General Meeting | 20-Aug-2015 |
| 2 | Annual General Meeting | 18-Sep-2014 |
| 2 | Annual General Meeting | 07-Aug-2013 |
| 2 | Dividend-Rs.10/- Per Share | 07-Jul-2011 |
| 2 | Dividend-Rs.10/- Pr Share | 06-May-2010 |
| 2 | Agm/Div-Rs.15/- Per Share | 29-Apr-2009 |
| 2 | Agm/Div-Rs15 Per Share | 11-Apr-2008 |
| 2 | Sch Of Agmt- Bonus Deb1:1 | 04-Jan-2008 |
| 2 | Agm Bc Start Date/Purpose Revised | 25-Apr-2007 |
| 2 | Int Div-Rs.12/- Per Sharepurpose Revised | 22-Mar-2007 |
| 2 | Fv Split Rs.10/- To Rs.2/ | 15-Jun-2006 |
Board Meetings of AstraZeneca Pharma India Limited
Financial Results of AstraZeneca Pharma India Limited
Company Directory of AstraZeneca Pharma India Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.astrazeneca.com/india | Registered Office | Block N1, 12 Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road | BANGALORE |
| www.astrazeneca.com/india | Transfer Agent | INTEGRATED REGISTRY MANAGEMENT SERVICES PVT LTD No. 30, Ramana Residency, 4th Cross, Sampige Rd., Malleswaram | BANGALORE |
Insider Trading of AstraZeneca Pharma India Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type | ||
|---|---|---|---|---|---|
| No insider trading information available | |||||
Annual Reports of AstraZeneca Pharma India Limited
Investor Complaints of AstraZeneca Pharma India Limited
Event Calendar of AstraZeneca Pharma India Limited
| Purpose | Details |
|---|---|
| Scheme of Arrangement | Inter alia, a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders pursuant to section 391 read with section 393 of the Companies Act, 1956, a draft of which Scheme will be tabled at the meeting for consideration. |
| Voluntary Delisting | The Company has inform the Exchange that the Board of Directors (Board) of AstraZeneca Pharma India Limited (Company) have received a letter from AstraZeneca Pharmaceuticals AB (AP AB), promoter of the Company, on June 28, 2010, proposing to make a voluntary delisting offer (the Delisting Offer) to the public shareholders of the Company in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Delisting Regulations) with a view to delist the equity shares of the Company from Bombay Stock Exchange (BSE), National Stock Exchange of India Limited (NSE) and Bangalore Stock Exchange Limited (BgSE) (collectively, Stock Exchanges), being the stock exchanges on which the equity shares are currently listed (the Delisting Proposal) under the Delisting Regulations. |
| Results/Dividend | Inter alia to consider and approve the Audited Financial Results of the Company for the quarter and financial year (15 Months) ended March 31, 2011 and to recommend dividend, if any. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2012. |
| Others | To consider the 'Strategy Plan' for the Company. |
| Results | Inter alia, to consider and approve the Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2013. |
| Results/Dividend | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 21, 2013 inter alia, to consider and approve the Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2013. The Company has now informed the Exchange that the Board of Directors at the aforesaid meeting, may also inter-alia consider 'recommendation of dividend' for the financial year ended March 31, 2013. (Purpose Revised) |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2013. |
| Delisting | To consider the Delisting Proposal and Matters incidental hereto. |
| Voluntary Delisting | With reference to the earlier announcement dated March 05, 2014 regarding the Outcome of the Board Meeting held on March 05, 2014, the company has now informed Exchange that the voluntary delisting proposal from AstraZeneca Pharmaceuticals AB, Sweden (AZP AB) in terms of their letter dated March 01, 2014 will be considered at the meeting of the Board of Directors of the Company to be held on March 15, 2014. |
| Delisting | To consider inter-alia seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009. |
| Results/Dividend | for considering Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2014 & may also consider 'recommendation of dividend' for the financial year ended March 31, 2014. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2014. The 'Trading Window' shall remain closed for all Specified Persons, from August 1, 2014 to August 13, 2014 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Preventiion of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider trading) Regulations, 1992. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014. Further the 'Trading Window' shall remain closed for all Specified Persons, from October 16, 2014 to November 4, 2014 (both days inclusive) in terms of Company - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2014. |
| Results | Inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and the year ended March 31, 2015. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2015. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2015. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2015. |
| Results/Others | Inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2016. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2016. Company would also like to inform that the Trading Window shall remain closed for all Designated Persons, from June 16, 2016 to August 11, 2016 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2016. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2016. |
| Results | inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2017. Further that the 'Trading Window' shall remain closed for all Designated Persons, from March 16, 2017 to May 11, 2017 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Results/Others | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2017. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2017. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | AstraZeneca Pharma India Limited has informed the Exchange about Board Meeting to be held on 08-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | AstraZeneca Pharma India Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of AstraZeneca Pharma India Limited
Voting Results of AstraZeneca Pharma India Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 22-DEC-2024 | Postal Ballot | Approval for appointment of Ms. Monica Widhani (DIN:07674403) as Director (Non-Executive and Independent) of the Company |
| 22-DEC-2024 | Postal Ballot | Approval for appointment of Mr. Jesus Javier Diaz Ropero Esteso (DIN: 10835384) as Director (Non-Executive) of the Company |
| 08-AUG-2024 | AGM | Adoption of Accounts for the year ended March 31, 2024 and the Reports of the Auditor￢ﾀﾙs and Director￢ﾀﾙs thereon |
| 08-AUG-2024 | AGM | Ratification of Cost Auditor￢ﾀﾙs remuneration |
| 08-AUG-2024 | AGM | Consent of members for the appointment of Dr. Sanjeev Kumar Panchal (DIN: 09823879) who retires by rotation, and being eligible, offers himself for re-appointment |
| 08-AUG-2024 | AGM | Declaration of dividend of Rs. 24/- per share on equity shares for the financial year 2023-24 |
| 30-JUN-2024 | Postal Ballot | Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited |
| 30-JUN-2024 | Postal Ballot | Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca AB, Sweden |
| 05-APR-2024 | Postal Ballot | Appointment of Ms. Bhavana Agrawal (DIN:10485441) as a Director and also as a Whole Time Director of the Company |
| 06-FEB-2024 | Postal Ballot | Appointment of Ms. Hooi Bien Chuah (DIN:10381891) as a Director (Non-Executive) of the Company |
| 06-FEB-2024 | Postal Ballot | Appointment of Ms. Sylvia Lorena Varela Ramon (DIN: 10410837) as a Director (Non-Executive) of the Company |
| 14-AUG-2023 | AGM | Adoption of Accounts for the year ended March 31, 2023 and the Reports of the Auditor￢ﾀﾙs and Director￢ﾀﾙs thereon. |
| 14-AUG-2023 | AGM | Ratification of Cost Auditor￢ﾀﾙs remuneration |
| 14-AUG-2023 | AGM | Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca AB, Sweden. |
| 14-AUG-2023 | AGM | Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited. |
| 14-AUG-2023 | AGM | Consent of members for the appointment of Ms. Weiying Sarah Wang (DIN: 08369289) who retires by rotation, and being eligible, offers herself for re-appointment. |
| 14-AUG-2023 | AGM | Declaration of dividend of Rs. 16/- per share on equity shares for the financial year 2022-23 |
| 25-FEB-2023 | Postal Ballot | Reappointment of Mr. Rajesh Marwaha (DIN: 01458768) as Whole TimenDirector of the Company. |
| 25-FEB-2023 | Postal Ballot | Appointment of Mr. Sanjeev Kumar Panchal (DIN: 09823879) as Directornand also as Managing Director of the Company. |
| 08-AUG-2022 | AGM | Adoption of Accounts for the year ended March.n31, 2022 and the Reports of the Auditor￢ﾀﾙs andnDirectors thereon |
FAQs on AstraZeneca Pharma India Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.